1 g of Solcoseryl Jelly contains: 4.15 mg of protein-free haemodialysate from calves' blood, chemically and biologically standardized; 1.73 mg of methyl parahydroxybenzoate (E 218); 0.27 mg of propyl parahydroxybenzoate (E 216).
1 g of Solcoseryl Ointment contains: 2.07 mg of protein-free haemodialysate from calves' blood, chemically and biologically standardized; 1.6 mg of methyl parahydroxybenzoate (E 218); 0.2 mg of propyl parahydroxybenzoate (E 216).
Pharmacology: Pharmacodynamics: Solcoseryl is a protein-free haemodialysate and contains a large number of low-molecular components of cells and serum of calf blood (dialysis/ultrafiltration, cut-off 5,000 Da), which until now have only partly been characterized chemically and pharmacologically.
In various cell and tissue cultures, in organs and in the animal organism, it was found that Solcoseryl: fosters/stimulates the aerobic energy metabolism and oxidative phosphorylation and thus the provision of high-energy phosphates in undersupplied cells,
Increases oxygen utilization (in vitro) and glucose transport in hypoxic and metabolically depleted tissues and cells,
Improves the processes of repair and regeneration of damaged and/or under-served tissue,
Prevents or reduces secondary degeneration and pathological changes in reversibly damaged cell systems,
Increases collagen synthesis in in vitro models, and
Stimulates cell proliferation and migration in vitro.
Solcoseryl thus promotes the re-functionalization of hypoxia and/or lack of substrate of reversibly damaged tissue and speeds up as well as improves the quality of the healing of lesions.
Pharmacokinetics: Absorption, distribution and elimination of the protein-free haemodialysate active ingredient cannot be analysed by conventional pharmacokinetic methods such as radioactive labeling etc. because protein-free haemodialysate has a variety of pharmacodynamic effects which are attributable to molecules with different physiochemical properties.
Solcoseryl Jelly and Ointment contain a haemodialysate from calves' blood to promote healing.
The products are suitable for treating minor and poorly healing wounds and ulcers of the skin.
Solcoseryl Jelly promotes wound healing. The Jelly is particularly used for treating venous stasis ulcers, decubital ulcers, acute and chronic dermatitis, secondary and tertiary burns.
Solcoseryl Ointment promotes the healing of dry wounds. It is particularly suitable for minor burns and abrasions. It is used in combination with the Jelly for deep, poorly healing wounds to protect the newly formed skin. This reduces the healing time and results in cosmetic improvement in the scarring.
Recommended Dosage: Solcoseryl Jelly is applied thinly 2-3 times a day.
Duration of treatment: until fresh skin tissue has formed. It is advisable to cover the newly formed skin at the edge of the poorly healing wounds and ulcers using Solcoseryl Ointment. Before application of the product, recent, weeping abrasions should be dried with a clean piece of gauze.
Solcoseryl Ointment is applied thinly 1-2 times a day and covered with a dressing. Do not massage in.
Duration of treatment: until the wound has completely healed.
Use the dosage indicated in this package insert or prescribed by the physician. If the patient thinks the effect of the medicine is too weak or too strong, speak to the physician or pharmacist.
Route of administration: Topical use.
Toxic effects from overdosage of Solcoseryl Jelly or Ointment have not been reported.
In cases of hypersensitivity or allergy to parahydroxybenzoates (E 210, E 216, E 218) which are present as preservatives.
No special precautions are necessary on use in accordance with the instructions.
Reproduction studies in animals have not shown any risks to the fetus, but there are no controlled studies in pregnant women. When used in pregnancy caution must exercised. There are no concerns with the application of Solcoseryl Jelly and Ointment during lactation.
In very rare cases, hypersensitivity reactions may occur. If unusual skin reactions occur, discontinue the product and inform the physician or pharmacist. After application of Solcoseryl Jelly, an unpleasant stinging may occur for a short time. This does not mean the product should be discontinued.
No interactions with other agents have been reported.
The medicine should be stored at temperature below 30°C.
Shelf-Life: 5 years.
D03AX - Other cicatrizants ; Used in the treatment of wounds and ulcers.
Solcoseryl Jelly 4.15 mg (colourless, homogenous, clear gel of high consistency) x 20 g. Solcoseryl Ointment 2.07 mg (white to slightly yellowish, homogenous, fatty mass and is easily spreadable) x 20 g.